MedPath

High Dose Chemotherapy and Autologous Transplant for Breast Cancer

Phase 2
Conditions
Graft vs Host Disease
Registration Number
NCT00186641
Lead Sponsor
Stanford University
Brief Summary

To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Stage II, III or IV breast cancer
  • chemosensitive
  • adequate organ function
Exclusion Criteria
  • prior transplant,
  • life threatening disease
  • brain metastases

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Survival
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Stanford University Cancer Center

🇺🇸

Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath